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Summary and Key Points 
1. The incidence, distribution, treatment, and survivorship of childhood 
cancer differ in many ways from malignancies found mainly in adults. 
2. It is important to be able to recognize typical clinical presentation of 
common childhood hematologic and solid tumor malignancies. 
3. Chemotherapy, radiation therapy, and surgery all have critical roles 
to play in the treatment of common childhood cancers and 
improvements in each have improved survival rates. 
4. Treatment and outcomes of childhood cancer differ with the age of a 
child. 
5. At least 328,000 Americans alive today are survivors of childhood 
cancer with increased health care needs. 
Perspective 
Cancer is a rare disease among children less than 20 years of age with 
an age-adjusted incident rate of approximately 16 per 100,000.1 
However, cancer is “second” only to accidents (i.e. unintentional injuries) 
and homicides/suicides as a cause of death in children between 1 and 
19 years of age.1 
Cancer treatment and survival for children differ widely from adults in 
many ways. Chemotherapy treatment in children may be more intense 
and frequent because dose-limiting toxicities are reached at higher 
doses than in adults who commonly have more health issues and co-
morbidities than children. Childhood and adult cancers also differ 
biologically which may be relevant to therapeutic response and survival 
differences. Most adult cancers are carcinomas derived from epithelial 
tissue, whereas a majority of pediatric cancers derive from developing 
tissue of mesodermal and ectodermal embryonic origin such as bone 
marrow, nerve tissue, lymph nodes, bone, and muscle. Experience has 
shown that “blastic” cancers that arise from primitive tissues are more 
responsive to therapy, especially chemotherapy, than carcinomas.5 
Treatment outcomes for children and adolescents with cancer have 
improved dramatically over the last 3 decades with 82% of children ages 
0-19 years during 2001-2007 surviving 5 years after diagnosis of cancer 
compared to only 61% during the period 1975-1977.2 Table 1 illustrates 
the statistically significant improvement of relative survival rates of 
children with cancer over 25 years and differences in survival between 
different age groups. This progress is a result of advances in multimodal 
and combination drug therapies and supportive care, participation in 
systematic cooperative group clinical trials, and recognition that “children 
are not small adults.” Indeed, the results of treatment of children with 
cancer have been shown to be superior when specialized care is 
directed by a pediatric cancer center3 and studies have shown that 
adolescents with acute lymphoblastic leukemia had a better outcome 
when treated on pediatric cooperative group trials versus adult 
cooperative group trials.4 
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Toxicities of cancer treatments including chemotherapy, radiation 
therapy, and surgical therapies, however, may have more significant and 
irreversible effects on children than on adults because of the active 
growth and development of most organ systems during childhood and 
adolescence. Radiation therapies, for example, that may represent 
standard of care for adult cancer, may be contraindicated for children 
because of the effects on the developing brain and growing bones. 
Fortunately, evolution of successful multimodality treatments for children 
with cancer allows for reduction of intensity and duration of individual 
therapies including the use of more conservative radiation and surgical 
procedures and chemotherapy to minimize the late effects of these 
therapies. This concept is highlighted by contemporary protocols for 
treatment of extremity sarcomas combining multidrug adjuvant 
chemotherapy to treat occult disseminated disease and decrease the 
size of primary tumor and allowing for improved local control therapy 
utilizing limb salvage surgery enhanced with radiation therapy. This 
concept is also seen in protocols for treatment of low stage Hodgkin 
lymphoma in children with multidrug chemotherapy and reduced intensity 
involved field radiation therapy. 
Long term toxicities or late effects of cancer therapies that may be more 
significant in children include growth of muscles and bones, dental 
abnormalities such as tooth agenesis, hearing loss, learning deficits, 
heart problems, lung problems, and psychosocial disorders including 
social withdrawal and educational problems. 
 
The Children’s Oncology Group (COG) has published a web-based 
resource for physicians called “Long-Term Follow-Up Guidelines for 
Survivors of Childhood, Adolescent, and Young Adult Cancers” 
http://www.survivorshipguidelines.org. 
 
Acute Lymphoblastic Leukemia (ALL) 
Leukemia is the most common cancer diagnosed in children 
representing about 25% of all cancer cases among those younger than 
20 years of age. There are multiple types of leukemia. Table 2 illustrates 




Clinical signs and symptoms of ALL in children are non-specific and 
manifestations of the failure of normal hematopoesis, immune 
suppression, and visceral organ infiltration; hepatosplenomegaly is the 
most common finding. ALL may present with hilar and mediastinal 
adenopathy. (Table 3) Duration of symptoms in children presenting with 
ALL may vary from days to less commonly months. 
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Laboratory findings in children with ALL include abnormal complete 
blood count (CBC) with pancytopenia, elevated sedimentation rate, and 
identifiable blast cells on peripheral blood smear which may be present. 
Isolated thrombocytopenia is a rare event in ALL6 and total white blood 





Radiologic findings in ALL include mediastinal mass on chest x-ray in 5 – 
10% of all cases and 75% of cases of T-cell ALL, skeletal abnormalities 
(diffuse or localized) on plain radiographs in 50% of cases, 
organomegaly (liver, spleen, kidneys), and increased uptake on 
radionuclide bone scans (Figure 1). 
 
 
Figure 1. Whole Body Tc-99m MDP Bone Scan of a 15 year old male with ALL 
presenting with fever and back pain showing tracer activity in L2 and L3 
vertebrae. University of Massachusetts Medical School. 
 
 
Diagnosis of ALL requires examination of peripheral blood and bone 
marrow aspiration with/without bone marrow biopsy for morphology 
(Figure 2), immunophenotyping, and cytogenetic (karyotype, FISH) and 
molecular analyses. Bone marrow examination to evaluate for leukemia 
is indicated in a child with abnormal CBC and “blast forms”, abnormal 
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Figure 2. Bone Marrow Aspiration Smear from a 3 year old male presenting with 
ALL (CBC with WBC of 9,600/mm3 (neutrophil count 480/mm3), hemoglobin 
9.4g/dL, and platelets 130,000/mm3) showing hemodilute bone marrow and 
infiltration of L1 lymphoblasts. [               ] (60x) University of Massachusetts 
Medical School. 
 
Risk stratification of factors for survival in childhood ALL is based on age 
and WBC at diagnosis (favorable outcome for ages 1-9 years and WBC 
< 50,000/mm3), genetic/molecular subtype of ALL (e.g. presence of 
t(9;22) translocation is a very high risk feature), and early treatment 
response (i.e. residual leukemic blasts in bone marrow at ‘day 8’ or ‘day 
15’ and minimal residual disease measured by multiparameter flow 
cytometry at ‘day 29’ of induction chemotherapy). 
Successful therapy for ALL in children requires multidrug chemotherapy 
given in phases: induction, intensification or consolidation, and 
maintenance as well as treatment or prophylaxis of extramedullary 
disease sites- central nervous system (CNS) and testes in boys. 
Treatment or prophylaxis of CNS disease is done with intrathecal 
chemotherapy. Cranial irradiation is reserved for those children with 
excessive CNS disease at diagnosis. Boys with persistent testicular 
disease receive testicular radiation. 
 
Brain/Central Nervous System Tumor 
Central nervous system (CNS) tumors represent 16.7 % of all cancers in 
children less than 20 years of age with an annual incidence rate of 30 
per million. CNS tumors are the most common solid tumor cancers in 
children.1 
Astrocytic tumors, including all grades of astrocytomas and glioblastoma 
multiforme, account for 52% of all CNS cancer in children less than 20 
years of age, followed in frequency by primitive neuroectodermal tumors 
including medulloblastoma (21%), other gliomas including 
oligodendrogliomas (15%), ependymomas (9%), craniopharyngiomas, 
and choroid plexus tumors. 
Over 90% of CNS cancers in children are located in the brain. Unlike 
adults, a majority of brain tumors in children occur infratentorially in the 
cerebellum and brainstem and present with diplopia, gait problems, 
nystagmus, and weakness. Supratentorial tumors in the frontal, 
temporal, parietal, and occipital lobes and thalamic/basal ganglia present 
with localizing focal and nonlocalizing (change in affect, energy level, 
motivation, and behavior, sexual precocity, delayed puberty, growth 
failure, somnolence, and autonomic abnormalities) signs and symptoms 
and seizures. These include increased intracranial pressure (headache, 
vomiting, and papilledema) and are usually late findings of a child with a 
brain tumor (Figure 3). 
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Figure 3. MRI of Brain with well-defined tumor in posterior fossa and 
hydrocephalus of supratentorial ventricles [] in an 8 year old male with 
medulloblastoma presenting with 1 week of morning headache and vomiting. 
University of Massachusetts Medical School. 
 
Initial staging of a brain tumor requires imaging of brain and spinal cord 
to evaluate for spinal metastases with magnetic resonance imaging 
(MRI). Brain tumors in children are treated with combined-modality 
therapy. Complete surgical resection, if possible, is preferred. Adjuvant 
chemotherapy and radiation therapy are given after recovery from 
surgery. Low grade tumors may be treated with complete surgical 
resection and observation. Radiation therapy is usually restricted in 
children under 3 years of age because of neurotoxicity, however, recent 
advances in radiation therapy technology, primarily in three-dimensional 
image-based conformal treatment fields, appear to decrease the 
morbidity associated with radiation. 
 
Non-Hodgkin Lymphoma and Hodgkin Lymphoma 
Lymphomas account for 15.5% of all cancers in children less than 20 
years of age with an annual incidence of 26 per million making them the 
third most frequent cancer in children (lymphoma is the most common 
cancer in adolescents 15-19 years of age).1  
Lymphomas are malignancies of lymphoid cells (B or T lymphocytes) 
and are classified as either Hodgkin disease (HD) or non-Hodgkin 
lymphoma (NHL). HD is an unusual lymphoma in which the malignant or 
Reed-Sternberg cells appear to originate from a B-lymphoid cell and 
compose only a small percentage of the tumor. 
NHL is more common in younger children and HD more common in 
adolescents. HD has a bimodal age distribution with peak incidence in 
the 3rd and 6th decade of life and is rarely diagnosed before 5 years of 
age. The most common histologic subtype of HD in children is the 
nodular sclerosis subtype (70%). 
In children, almost all of NHL is of high grade, unlike adults where low 
and intermediate grade lymphomas are more common. The predominant 
histopathologic subtypes of NHL are anaplastic large cell lymphoma, 
Burkitt and Burkitt-like (small noncleaved cell) lymphoma, diffuse large B-
cell lymphoma, and lymphoblastic lymphoma (precursor T- or precursor 
B-cell), each with distinctive molecular and biological characteristics. The 
lymphoblastic lymphomas are indistinguishable histologically from their 
acute lymphoblastic leukemia counterparts. 
Lymphoma typically presents with painless localized or regional lymph 
node enlargement and tumor mass (Figure 4). Extranodal involvement is 
much more common in NHL. Constitutional or ‘B’ symptoms occurring in 
30% of patients with HD include unexplained fever, weight loss, and 
drenching night sweats. 
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Figure 4. CXR Showing Mediastinal Adenopathy in a 13 year old male with HD 
presenting with several month history of neck adenopathy. University of 
Massachusetts Medical School. 
 
Evaluation for lymphoma includes: 
• Complete blood count and sedimentation rate (ESR) 
• Bone marrow aspiration and biopsy 
• Radiology staging with  
• Chest/abdomen/pelvis computed tomography 
• Chest x-ray 
• Positron emission tomography (PET) or gallium scan 
• Bone scan if indicated 
Diagnosis is made by surgical incisional biopsy (Figures 5A & 5B); fine-
needle aspiration biopsy may not be adequate for diagnosis of 
lymphoma in children. Lymph node biopsies should be sent for routine 
histology, immunohistochemistry, molecular/cytogenetic analysis, and 
immunophenotyping by flow cytometry. 
 
Figure 5a. Incisional Lymph Node Biopsy of Neck shows effacement of lymph 
node with fibrous bands [] in a 13 year old male with several month history of 
neck adenopathy without ‘B’ symptoms, ESR 79, and CXR with mediastinal 
mass. (Hematoxylin-eosin stain; 2x) University of Massachusetts Medical School. 
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Figure 5b. Incisional Lymph Node Biopsy of neck shows lacunar cells (Reed-
Sternberg cell variant caused by cytoplasmic shrinking during formalin fixation) 
consistent with a diagnosis of nodular sclerosing HD in same patient. [] 
(Hematoxylin-eosin stain; 60x) University of Massachusetts Medical School. 
 
Treatment for NHL includes multiagent chemotherapy ± central nervous 
system prophylaxis based on tumor stage for less than 1 year except for 
lymphoblastic lymphoma which requires longer maintenance 
chemotherapy. HD is treated with multiagent chemotherapy for less than 
6 months and involved field radiation therapy. 
 
Neuroblastoma 
Sympathetic nervous system tumors represent 5.4% of all cancers in 
children less than 20 years of age with an annual incidence rate of 7 per 
million in children less than 15 years of age; approximately 95% of these 
tumors are neuroblastoma and ganglioneuroblastoma.1 Most cases of 
neuroblastoma are diagnosed before 4 years of age and neuroblastoma 
is the most common cancer of infancy and the most common 
extracranial solid tumor cancer in children. 
The 5-year relative survival rate from 1985-1994 for infants with 
neuroblastoma is 83% compared with 55% for children 1 to 4 years of 
age and reflects the favorable biological features of neuroblastoma 
occurring in infants.1 
Neuroblastoma is an embryonal malignant neoplasm arising from 
primitive adrenergic neural crest cells in the adrenal medulla, 
sympathetic ganglia, and sympathetic paraganglia. Neuroblastoma can 
arise from any site along the sympathetic nervous system chain, adrenal 
gland, and organ of Zuckerkandl in the pelvis. Most primary tumors are 
found in the abdomen (60%), adrenal gland (35%), and retroperitoneum 
(25%), and thorax in the posterior mediastinum (15%). Histologically, 
neuroblastoma is one of the “small, round blue cell tumors” of childhood. 
Amplification of MYCN proto-oncogene occurs in 20% to 25% of 
neuroblastomas and is a reliable marker of aggressive clinical behavior.7 
The presenting signs and symptoms of neuroblastoma depend on the 
location of the primary tumor, presence of metastatic disease (bone 
marrow, bone, liver, and skin), and paraneoplastic effects (e.g. 
opsomyoclonus and intractable secretory diarrhea) seen in a minority of 
children. Paraspinal thoracic and retroperitoneal tumors may present 
with spinal cord compression representing anoncologic emergency, 
cervical tumors may present with Horner syndrome, and orbital bone 
metastatic disease may present with periorbital ecchymoses (“raccoon 
eyes”) and proptosis. 
Laboratory findings in a child with neuroblastoma include elevation of the 
urinary catecholamine metabolites vanillylmandelic (HVA) and 
homovanillic acid (VMA). Serum LDH and ferritin or the complete blood 
count may show evidence of metastatic bone marrow disease. Plain 
radiographs may show mass with calcifications (Figure 6). 
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Figure 6. Plain Abdominal Radiograph showing large right upper quadrant mass 
with calcifications [] in a 2 year old female with unfavorable histology, N-MYC 
amplified metastatic neuroblastoma of right adrenal gland presenting with 
abdominal swelling and fever; random urine sample showed elevated HVA and 
VMA. University of Massachusetts Medical School. 
 
Initial evaluation and staging of neuroblastoma requires computed 
tomography or magnetic resonance imaging of the primary tumor and 
suspected metastatic sites, bone scan, metaiodobenzylguanidine (MIBG) 
scan, and bilateral bone marrow biopsies/aspirates. Surgical incisional 
biopsy is usually required to confirm diagnosis and obtain adequate 
tissue for genetic and molecular biology studies essential for determining 
therapy. 
Neuroblastoma has remarkable clinical heterogeneity and therapy is risk-
stratified based on age, tumor stage, MYCN status, histopathologic 
classification, and other biologic factors that are under study. Low-risk 
patients are usually treated with surgery alone and high-risk patients are 
treated with multimodal treatment including dose intensified and high-
dose chemotherapy with autologous stem cell support, radiation therapy 
for bulky residual disease, and biologic therapy with 13-cis retinoic acid. 
 
Osteosarcoma/Ewing Bone Sarcoma 
Bone tumors represent 5.6 % of all cancers in children less than 20 
years of age with an annual incidence rate of 8.7 per million. 
Osteosarcoma and Ewing sarcoma (EWS) account for 56% and 34% 
respectively of malignant bone tumors in children. The incidence of bone 
cancer is characterized by a steady rise in rate beginning at 11 years of 
age with a peak incidence at 15 years of age coinciding with the 
adolescent growth spurt.1 
The 5-year survival rates from 1985-1994 for osteosarcoma and Ewing 
bone sarcoma were 63% and 58% respectively; children with EWS of the 
pelvis have a poor survival outcome.1 
Osteosarcoma arises from primitive bone mesenchymal cells and usually 
occurs at the metaphyses of tubular bones. The most frequent primary 
sites are distal femur and proximal tibia. (Figures 7A & 7B) EWS is 
believed to arise from cells of neural crest origin and usually occurs at 
the diaphyses of tubular bones and flat bones. The most frequent 
primary sites are pelvis, femur, tibia, and humerus. (Figure 8) About 95% 
of patients with EWS have a t(11;22) or t(21;22) genetic translocation 
involving the EWS gene on chromosome 22. Clinically detectable 
metastases to other bones and lung (and bone marrow in cases of EWS) 
are found in about 20 - 25% of patients at time of diagnosis.8 
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Figure 7a. Plain Radiograph of Right Femur in an 18 year old male with non 
metastatic osteosarcoma presenting with 1 month history of intermittent right 
knee pain showing osteolytic lesion centered at distal metaphysis of femur. 





Figure 7b. MRI of Right Femur in same patient showing a large intramedullary 
lesion. University of Massachusetts Medical School. 
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Figure 8. MRI of Pelvis evidencing soft tissue mass arising from right ilium in a 
10 year old female with metastatic Ewing sarcoma (FISH evaluation positive for 
rearrangement of EWS gene) presenting with 6 months history of right hip pain, 
weight loss, fever, and elevated LDH. University of Massachusetts Medical 
School. 
 
Bone tumors present with pain or swelling in a bone or joint and an 
associated mass. Laboratory findings may include elevated serum 
lactate dehydrogenase (LDH) and alkaline phosphatase. 
Initial evaluation and staging of osteosarcoma/Ewing bone sarcoma 
requires anatomic imaging of primary tumor with magnetic resonance 
imaging (MRI) and plain radiographs. Metastatic sites are evaluated with 
a chest computed tomography scan (CT) and functional whole body 
imaging (bone scan or positron emission tomography (PET)). Surgical 
incisional biopsy is preferred over needle biopsy to confirm diagnosis 
and obtain tissue for genetic and molecular biology studies.  
Osteosarcoma/Ewing bone sarcoma in children are treated with 
combined-modality therapy with neoadjuvant chemotherapy to decrease 
the size of primary tumor followed by local control therapy (surgery for 
osteosarcoma; surgery and/or radiation therapy for EWS) and adjuvant 
consolidative chemotherapy after local therapy.  
 
Wilms Tumor 
Renal tumors represent 4.4 % of all cancers in children less than 20 
years of age with an annual incidence rate of 6.2 per million. 
Nephroblastoma or Wilms tumor (WT) account for 92% of renal cancer in 
children. WT is the most common renal cancer in children and 
approximately 75% of cases are diagnosed before 5 years of age.1 
WT is an embryonic neoplasm arising from primitive kidney cells or 
nephrogenic rests and may occur in a few children as part of a genetic 
syndrome (e.g. Beckwith-Wiedemann syndrome, WAGR syndrome). 
Histologic classification of Wilms tumors is based on extent of anaplasia. 
The classic symptom of WT is a painless abdominal mass often noted by 
a parent while bathing or dressing their child (Figure 9). WT may present 
with change in bowel habits, abdominal pain, vomiting, and weight loss. 
Signs of hypertension, microscopic hematuria, and metastatic disease to 
the lungs may also be seen at diagnosis. 
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Figure 9. CT of Abdomen with large mass arising from right kidney in a 2 year 
old male with Stage 1 WT with favorable histology presenting with painless mass 
in right upper quadrant. University of Massachusetts Medical School. 
 
Initial evaluation and staging of WT requires computed tomography (CT) 
or magnetic resonance imaging of the primary tumor, chest CT, and plain 
radiograph of the chest and sometimes ultrasound of renal vessels to 
evaluate for tumor thrombus. Unilateral radical nephrectomy and tumor 
excision is indicated at time of diagnosis unless tumor should be 
considered unresectable by the surgeon. 
WT is treated with multi-agent chemotherapy and radiation therapy to 
primary and metastatic tumor. Radiation therapy is omitted in patients 
with WT without anaplastic histology who have complete resection of 
tumor (Stage 1 and 2) at time of diagnosis. 
 
Rhabdomyosarcoma 
Soft tissue sarcomas represent 7.4 % of all cancers in children less than 
20 years of age with an annual incidence rate of 11 per million. 
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma 
and accounts for 40% of these cancers with an incidence of 4.3 per 
million in children less than 20 years of age.1 The 5-year survival rates 
from 1985-1994 for RMS was 64%; embryonal RMS has a superior 
outcome compared to alveolar RMS subtype.1 
RMS arises from striated muscle mesenchymal cells and can occur at 
any site. (Figure 10) The 2 most common histologic subtypes are 
embryonal RMS and alveolar RMS. Embryonal RMS is the most 
common subtype in children accounting for 75% of cases. However, the 
relative percentage of embryonal RMS subtype decreases with 
increasing age and alveolar RMS occurs more commonly than 
embryonal RMS at extremity sites. Most cases of alveolar RMS are 
characterized by recurring genetic translocations involving the FKHR 
gene on chromosome 13 while embryonal RMS generally has a loss of 
heterzygosity at chromosome 11p15.5. Clinically detectable metastases 
to regional lymph nodes, lungs, bone, and bone marrow are found in 
about 15 percent of patients at time of diagnosis.8 
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Figure 10. MRI of Abdomen and Pelvis in an 8 year old male with non-metastatic 
embryonal rhabdomyosarcoma presenting with 1 week history of left leg pain and 
limp showing large heterogenous retroperitoneal soft tissue mass in left side of 
pelvis. University of Massachusetts Medical School. 
 
Soft tissue sarcomas can present with a painless soft-tissue mass. RMS 
of the orbit may present with proptosis. 
Initial evaluation and staging of RMS requires imaging of primary tumor 
with magnetic resonance imaging or computed tomography and imaging 
to evaluate for metastatic disease with chest computed tomography and 
whole body bone scan. Surgical incisional biopsy or total excisional (35% 
of children have resectable tumors at diagnosis) biopsy, when possible, 
is preferred to confirm diagnosis and obtain tissue for genetic and 
molecular biology studies. Surgical sampling of ipsilateral inguinal or 
axillary lymph nodes is required in patients with RMS of the extremities.  
RMS is treated with multi-agent chemotherapy and radiation therapy 
along with surgery to primary and metastatic tumor. RMS tumors that are 
initially unresectable are treated with neoadjuvant chemotherapy to 
decrease the size of primary tumor followed by surgical resection (if 
feasible), local control radiation therapy, and consolidative chemotherapy 
after local control therapy. 
 
Summary 
Cancer is a rare disease in children; however, it is the leading cause of 
disease-related mortality among children 1 to 19 years of age. The most 
common childhood cancers (leukemias and lymphomas, osteosarcoma 
and Ewing sarcoma, Wilms tumor, and rhabdomyosarcoma), excluding 
those arising from the brain/central and sympathetic nervous system, 
originate from mesenchymal cells and, unlike the more common 
epithelial carcinomas in adults, are associated with spontaneous 
chromosomal translocations generating fusion oncogenes. Outcomes for 
children with cancer have improved significantly over the last 25 years as 
a result of disease risk stratification and multidisciplinary and multimodal 
approach to disease therapy. Advances in childhood cancer treatment 
have meant that at least 328,000 of the more than 10 million cancer 
survivors that are alive in the United States were originally diagnosed 
with cancer under the age of 21.  
However, this success has a price, as cancer treatment in children may 
cause health problems that may develop years after successful 
treatment and are called late effects. Because of this, childhood cancer 
survivors require close, life-long follow-up. The Childhood Cancer 
Survivor Study (CCSS) was started in 1993 to better understand these 
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Thought Questions 
1. Which of the following variables is usually least predictive of survival 
in children with cancer: age at diagnosis, stage of cancer, biologic 
characteristics of cancer cell, early response to treatment? List 1 or 2 
single predominant prognostic factors of cure rate for the following 
childhood cancers: acute lymphoblastic leukemia, neuroblastoma, 

































2. A 3 year old presents with right-sided flank pain and a right 
abdominal mass. A 63 year old presents with right-sided flank pain 
and a right abdominal mass. CT scans in each patient show large 
right renal masses. How are these masses likely to be different from 
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3. Why have survival rates for most childhood cancer improved more 































4. As children with cancer survive their original tumor and live into 
adulthood, they may develop new cancers. Some new cancers in 
survivors of childhood malignancies are clearly related to previous 
treatment (e.g., breast cancer in women who received chest 
irradiation in adolescence). However, some new cancers in these 
patients may be due to an underlying susceptibility to developing 
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5. Why do physicians and members of the lay community consider risks 



























Adenopathy- Abnormal lymph nodes 
Autologous stem cell support- Use of autologous hematopoietic stem 
cells to rescue patients from profound myelosuppression or 
myeloablation that has been caused by chemotherapy or radiation 
Chemotherapy consolidation- Use of chemotherapy in a patient whose 
tumor is in remission in order to improve the chance of cure 
Chemotherapy intensification- Use of increasing doses of chemotherapy 
Chemotherapy maintenance- Use of ongoing courses of chemotherapy 
to lower risk of recurrence in a patient whose cancer is in remission 
Ectodermal embryonal tissue- One of the three primary germ layers in 
the embryo; differentiates to form the nervous system. 
Extramedullary leukemia- Leukemia in sites other than bone marrow, 
e.g. central nervous system, testes (in boys) 
Hematopoesis- Production of blood cells 
Hepatosplenomegaly- Enlarged liver and spleen 
Induction chemotherapy- Initial chemotherapy that is used to treat a 
patient’s cancer; so-called because the goal is to “induce” a remission 
Intrathecal chemotherapy- Chemotherapy delivered directly into the 
cerebrospinal fluid 
Leukemia- Malignancy of hematopoietic cells 
Mesenchymal- Refers to cells that develop into connective tissue, blood 
vessels, and lymphatic tissue 
Mesodermal- Embryonal tissue pertaining to or derived from the middle 
layer of the three primary germ layers of the embryo which derive 
connective tissue, bone and cartilage, muscle, blood and blood vessels, 
lymphatics and lymphoid organs, pleura, pericardium, peritoneum, 
kidney, and gonads 
Neoadjuvant chemotherapy- Chemotherapy given prior to surgical 
resection of tumor 
Organomegaly- Enlargement of organs 
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Pancytopenia- Reduced levels of multiple hematopoietic cell lines; as 
opposed to anemia (reduced red blood cells), leucopenia (low white 
blood cell levels), or thrombocytopenia (low platelet levels) 
Prophylactic treatment- Treatment (prophylaxis) to prevent the 
development of a disease 
WAGR syndrome- Wilms tumor, aniridia, genitourinary abnormalities, 
and mental retardation/intellectual disability syndrome that affect the 
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